IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
Highlights
Cendakimab significantly reduced the frequency of dysphagia days compared to placebo at 24 weeks, achieving a mean reduction of 6.1 days.
Histologic response (≤6 eosinophils per high-power field) was achieved in 28.6% of patients receiving cendakimab once weekly, compared to only 2.2% in the placebo group.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.